Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.07
(0.87%)
USD 4.07
(0.87%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 43.04 Million USD | -9.24% |
| 2022 | 38.59 Million USD | 10.75% |
| 2021 | 34.85 Million USD | -0.91% |
| 2020 | 35.16 Million USD | -2.99% |
| 2019 | 36.25 Million USD | -11.04% |
| 2018 | 40.75 Million USD | 7.64% |
| 2017 | 37.86 Million USD | 32.85% |
| 2016 | 28.5 Million USD | 3.87% |
| 2015 | 27.43 Million USD | -3.01% |
| 2014 | 28.28 Million USD | -6.91% |
| 2013 | 30.38 Million USD | -13.14% |
| 2012 | 34.98 Million USD | -2.63% |
| 2011 | 35.93 Million USD | 0.4% |
| 2010 | 35.78 Million USD | 6.44% |
| 2009 | 33.62 Million USD | 35.87% |
| 2008 | 24.74 Million USD | 32.56% |
| 2007 | 18.66 Million USD | 41.51% |
| 2006 | 13.19 Million USD | 40.25% |
| 2005 | 9.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.87 Million USD | -9.69% |
| 2024 Q2 | 8.23 Million USD | 4.65% |
| 2023 Q2 | 9.34 Million USD | -1.69% |
| 2023 Q4 | 8.71 Million USD | -14.44% |
| 2023 FY | 35.03 Million USD | -9.24% |
| 2023 Q3 | 10.18 Million USD | 9.01% |
| 2023 Q1 | 9.5 Million USD | 8.63% |
| 2022 Q2 | 10.11 Million USD | -1.38% |
| 2022 Q3 | 9.47 Million USD | -6.29% |
| 2022 FY | 38.59 Million USD | 10.75% |
| 2022 Q4 | 8.75 Million USD | -7.66% |
| 2022 Q1 | 10.25 Million USD | 9.7% |
| 2021 Q4 | 9.34 Million USD | 12.53% |
| 2021 Q3 | 8.3 Million USD | -5.06% |
| 2021 Q2 | 8.75 Million USD | 3.63% |
| 2021 Q1 | 8.44 Million USD | -13.32% |
| 2021 FY | 34.85 Million USD | -0.91% |
| 2020 Q3 | 8.31 Million USD | -2.95% |
| 2020 FY | 35.16 Million USD | -2.99% |
| 2020 Q1 | 8.54 Million USD | -27.96% |
| 2020 Q2 | 8.56 Million USD | 0.31% |
| 2020 Q4 | 9.74 Million USD | 17.13% |
| 2019 FY | 36.25 Million USD | -11.04% |
| 2019 Q1 | 10.07 Million USD | -21.83% |
| 2019 Q4 | 11.85 Million USD | 15.15% |
| 2019 Q3 | 10.29 Million USD | 1.25% |
| 2019 Q2 | 10.17 Million USD | 0.9% |
| 2018 Q1 | 9.51 Million USD | -8.53% |
| 2018 FY | 40.75 Million USD | 7.64% |
| 2018 Q4 | 12.89 Million USD | 45.88% |
| 2018 Q3 | 8.83 Million USD | -7.05% |
| 2018 Q2 | 9.5 Million USD | -0.03% |
| 2017 Q1 | 8.91 Million USD | 5.69% |
| 2017 FY | 37.86 Million USD | 32.85% |
| 2017 Q4 | 10.39 Million USD | 5.36% |
| 2017 Q3 | 9.86 Million USD | 13.72% |
| 2017 Q2 | 8.67 Million USD | -2.63% |
| 2016 Q2 | 6.36 Million USD | -9.26% |
| 2016 Q3 | 6.68 Million USD | 5.07% |
| 2016 Q4 | 8.43 Million USD | 26.1% |
| 2016 FY | 28.5 Million USD | 3.87% |
| 2016 Q1 | 7.01 Million USD | 11.59% |
| 2015 Q2 | 6.99 Million USD | -6.94% |
| 2015 FY | 27.43 Million USD | -3.01% |
| 2015 Q1 | 7.52 Million USD | 7.1% |
| 2015 Q4 | 6.28 Million USD | -5.25% |
| 2015 Q3 | 6.63 Million USD | -5.21% |
| 2014 Q4 | 7.02 Million USD | -5.11% |
| 2014 FY | 28.28 Million USD | -6.91% |
| 2014 Q2 | 7.23 Million USD | 9.11% |
| 2014 Q1 | 6.63 Million USD | -21.86% |
| 2014 Q3 | 7.4 Million USD | 2.27% |
| 2013 FY | 30.38 Million USD | -13.14% |
| 2013 Q4 | 8.48 Million USD | 21.02% |
| 2013 Q1 | 7.82 Million USD | -5.41% |
| 2013 Q2 | 7.06 Million USD | -9.67% |
| 2013 Q3 | 7.01 Million USD | -0.77% |
| 2012 Q1 | 8.76 Million USD | -5.38% |
| 2012 FY | 34.98 Million USD | -2.63% |
| 2012 Q2 | 9.32 Million USD | 6.42% |
| 2012 Q3 | 8.63 Million USD | -7.44% |
| 2012 Q4 | 8.27 Million USD | -4.17% |
| 2011 Q2 | 9.47 Million USD | 11.84% |
| 2011 Q4 | 9.26 Million USD | 7.49% |
| 2011 FY | 35.93 Million USD | 0.4% |
| 2011 Q3 | 8.61 Million USD | -9.08% |
| 2011 Q1 | 8.47 Million USD | -10.96% |
| 2010 Q3 | 8.83 Million USD | -0.32% |
| 2010 FY | 35.78 Million USD | 6.44% |
| 2010 Q4 | 9.51 Million USD | 7.66% |
| 2010 Q1 | 8.46 Million USD | -8.4% |
| 2010 Q2 | 8.86 Million USD | 4.79% |
| 2009 Q2 | 8.44 Million USD | 28.91% |
| 2009 Q1 | 6.55 Million USD | -12.54% |
| 2009 Q3 | 9.46 Million USD | 12.02% |
| 2009 FY | 33.62 Million USD | 35.87% |
| 2009 Q4 | 9.23 Million USD | -2.41% |
| 2008 Q2 | 5.78 Million USD | 0.47% |
| 2008 Q1 | 5.75 Million USD | 7.73% |
| 2008 Q4 | 7.49 Million USD | 31.09% |
| 2008 Q3 | 5.71 Million USD | -1.13% |
| 2008 FY | 24.74 Million USD | 32.56% |
| 2007 Q2 | 4.69 Million USD | 14.83% |
| 2007 Q1 | 4.08 Million USD | -1.63% |
| 2007 Q4 | 5.34 Million USD | 17.39% |
| 2007 Q3 | 4.55 Million USD | -3.0% |
| 2007 FY | 18.66 Million USD | 41.51% |
| 2006 FY | 13.19 Million USD | 40.25% |
| 2006 Q1 | 2.56 Million USD | 0.0% |
| 2006 Q4 | 4.15 Million USD | 25.88% |
| 2006 Q2 | 3.17 Million USD | 23.93% |
| 2006 Q3 | 3.29 Million USD | 3.84% |
| 2005 FY | 9.4 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -421.522% |
| Alpha Teknova, Inc. | 45.85 Million USD | 6.146% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 78.039% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 4.043% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 72.966% |
| Cosmos Health Inc. | 26.18 Million USD | -64.397% |
| Journey Medical Corporation | 54.59 Million USD | 21.162% |
| Embecta Corp. | 528.4 Million USD | 91.855% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 84.17% |
| Dynavax Technologies Corporation | 219.14 Million USD | 80.36% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 92.705% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 86.813% |
| PainReform Ltd. | 9.58 Million USD | -349.088% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -227.941% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -227.941% |
| SCYNEXIS, Inc. | 51.84 Million USD | 16.987% |
| Safety Shot Inc | 12.1 Million USD | -255.422% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1302.343% |
| Procaps Group, S.A. | 199.47 Million USD | 78.423% |
| Theratechnologies Inc. | 72.75 Million USD | 40.843% |
| Harrow Health, Inc. | 89.97 Million USD | 52.163% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -355.648% |
| Biofrontera Inc. | 39.95 Million USD | -7.712% |
| DURECT Corporation | 43.71 Million USD | 1.543% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 91.864% |
| Cronos Group Inc. | 96.7 Million USD | 55.495% |
| OptiNose, Inc. | 85.1 Million USD | 49.425% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 81.458% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -9.929% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 550.168% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 86.299% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -342.311% |
| Radius Health, Inc. | 265.92 Million USD | 83.815% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -210.944% |
| ProPhase Labs, Inc. | 37.85 Million USD | -13.707% |
| Phibro Animal Health Corporation | 260.29 Million USD | 83.465% |
| Procaps Group S.A. | 187.24 Million USD | 77.014% |
| Alvotech | 285.43 Million USD | 84.921% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -338.072% |
| Viatris Inc. | 5.96 Billion USD | 99.279% |
| Rockwell Medical, Inc. | 15.37 Million USD | -179.957% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 28.074% |
| SIGA Technologies, Inc. | 22.04 Million USD | -95.257% |
| Tilray Brands, Inc. | 251.35 Million USD | 82.877% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 12.23% |
| Shineco, Inc. | 17.94 Million USD | -139.806% |
| PetIQ, Inc. | 192.72 Million USD | 77.667% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -978.403% |
| Incannex Healthcare Limited | 30.05 Million USD | -43.216% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 97.304% |
| Alimera Sciences, Inc. | 62.64 Million USD | 31.29% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -5544.722% |
| Assertio Holdings, Inc. | 368.58 Million USD | 88.323% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -631.289% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -141.685% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -103.319% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -104.545% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 73.909% |
| Hempacco Co., Inc. | 7.59 Million USD | -466.588% |
| Talphera, Inc. | 11.99 Million USD | -258.851% |
| Alvotech | 285.43 Million USD | 84.921% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 69.413% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 87.521% |
| Currenc Group, Inc. | 24 Million USD | -79.32% |
| Kamada Ltd. | 45.42 Million USD | 5.251% |
| Indivior PLC | 911 Million USD | 95.275% |
| Evoke Pharma, Inc. | 12.4 Million USD | -246.832% |
| Flora Growth Corp. | 10.57 Million USD | -306.849% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -104.545% |
| Evolus, Inc. | 189.75 Million USD | 77.318% |
| HUTCHMED (China) Limited | 436.23 Million USD | 90.134% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 72.076% |
| Akanda Corp. | 3.48 Million USD | -1135.552% |